Brian Rini

August 1, 2025

Study reports final clinical trial data for advanced kidney cancer treatment

The drug combo pembrolizumab plus axitinib had sustained and durable clinical benefit in more than five years of follow-up. It is a standard-of-care first-line treatment for advanced kidney cancer.

By Leigh MacMillan
July 22, 2025

Study provides new data on COVID outcomes for cancer patients 

Death incidence was highest in patients with lymphoma, intermediate in patients with acute leukemia and lung cancer, and lowest in patients with other solid tumors or with blood cancers other than lymphoma.

By Tom Wilemon
May 26, 2021

Vanderbilt researchers present new data on clinical trials at ASCO 2021

Vanderbilt-Ingram Cancer Center researchers will present data on clinical trials involving targeted therapies, immunotherapies and drug combination synergies at the 2021 American Society of Clinical Oncology Annual Meeting, June 4-8. The meeting is a virtual event this year.

By Tom Wilemon
November 10, 2020

Study underscores importance of personalized medicine in kidney cancer

A new study sheds light on how molecular subsets within the tumors of kidney cancer patients determine treatment outcomes and underscores the importance of personalized medicine in making therapy decisions.

By Tom Wilemon
October 29, 2020

Rini to lead NCI study of COVID-19 in cancer patients

Brian Rini, MD, is leading a study launched by the National Cancer Institute (NCI) that will closely monitor cancer patients who acquire COVID-19 with the goal of providing highly detailed data to guide future care.

By Tom Wilemon
May 28, 2020

Multinational consortium reports COVID-19 impact on cancer patients

People with cancer sickened by COVID-19 have a crude death rate of 13%, according to the largest series of data released thus far from a multinational perspective. The data on more than 900 patients, published May 28 in The Lancet and simultaneously presented at ASCO20 Virtual, also revealed cancer-specific factors associated with increased mortality.

By Tom Wilemon